title: In vitro efficacy of brincidofovir against variola virus.
abstract: Brincidofovir (CMX001), a lipid conjugate of the acyclic nucleotide phosphonate cidofovir, is under development for smallpox treatment using "the Animal Rule," established by the FDA in 2002. Brincidofovir reduces mortality caused by orthopoxvirus infection in animal models. Compared to cidofovir, brincidofovir has increased potency, is administered orally, and shows no evidence of nephrotoxicity. Here we report that the brincidofovir half-maximal effective concentration (EC50) against five variola virus strains in vitro averaged 0.11 μM and that brincidofovir was therefore nearly 100-fold more potent than cidofovir.
authors: Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Poxvirus and Rabies Branch, Atlanta, Georgia, USA.
authors: Victoria A
authors: VA
authors: Olson
authors: Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Poxvirus and Rabies Branch, Atlanta, Georgia, USA.
authors: Scott K
authors: SK
authors: Smith
authors: Chimerix, Inc., Durham, North Carolina, USA.
authors: Scott
authors: S
authors: Foster
authors: Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Poxvirus and Rabies Branch, Atlanta, Georgia, USA.
authors: Yu
authors: Y
authors: Li
authors: Chimerix, Inc., Durham, North Carolina, USA.
authors: E Randall
authors: ER
authors: Lanier
authors: Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Poxvirus and Rabies Branch, Atlanta, Georgia, USA.
authors: Irina
authors: I
authors: Gates
authors: Chimerix, Inc., Durham, North Carolina, USA.
authors: Lawrence C
authors: LC
authors: Trost
authors: Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Poxvirus and Rabies Branch, Atlanta, Georgia, USA iad7@cdc.gov.
authors: Inger K
authors: IK
authors: Damon
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D002522:Chlorocebus aethiops; D000077404:Cidofovir; D003596:Cytosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004279:DNA, Viral / Q000032:analysis / Q000235:genetics; D004195:Disease Models, Animal; D006801:Humans; D066298:In Vitro Techniques; D008826:Microbial Sensitivity Tests; D063065:Organophosphonates / Q000494:pharmacology*; D012899:Smallpox / Q000188:drug therapy*; D012901:Variola virus / Q000187:drug effects* / Q000254:growth & development
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D063065:Organophosphonates; C525733:brincidofovir; D003596:Cytosine; D000077404:Cidofovir